Evidence map›Paper›PMID 37813597›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2023

Chronic Enterovirus Meningoencephalitis in Prolonged B-Cell Depletion After Rituximab Therapy: Case Report.

Clemens Jacksch, Justina Dargvainiene, Sindy Böttcher, Sabine Diedrich, Frank Leypoldt, Klarissa Stürner, Daniela Berg, Eva Schäffer

Abstract readCase Reports
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases.Multiple sclerosis journal - experimental, translational and clinical
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Clemens JackschFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland. clemensjacksch@googlemail.com.
Justina DargvainieneFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.ORCID 0009-0002-4114-3748
Sindy BöttcherFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.
Sabine DiedrichFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.
Frank LeypoldtFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.ORCID 0000-0002-8972-515X
Klarissa StürnerFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.
Daniela BergFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.
Eva SchäfferFrom the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPersistent impaired immunity is possible even years after B-cell depleting therapies. This may favor the occurrence of infections, including infectious meningitis and encephalitis. In this study, we report a case of chronic enterovirus meningoencephalitis in prolonged B-cell depletion years after rituximab therapy.

methodsThis is a case report from a German academic hospital. In addition to repeated clinical examinations, repeated brain MRI and extended CSF and laboratory diagnostics were performed. We used the CARE checklist when writing our report.

resultsA 38-year-old man presented with high fever (>40°C), severe headache, and progressive neurologic and cognitive deficits. As result of previous lymphoma therapy with rituximab years ago, prolonged B-cell aplasia was detected. To restore humoral immunity, the patient received repeated infusions of immunoglobulins. In the end, a complete restitution of the physical and mental condition was achieved with the established therapy. DISCUSSION: This case report should emphasize the importance of assessing humoral immunity even years after B-cell depletion therapy, especially in case of opportunistic infections.

Indexed as

EnterovirusEnterovirus InfectionsMeningoencephalitisAdultB-LymphocytesHumansMaleRituximabRituximab

Identifiers

PMID37813597
PMCPMC10574820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.